Low risk of traumatic intracranial hematoma expansion with factor Xa inhibitors without andexanet reversal.
Sign Up to like & getrecommendations! Published in 2020 at "World neurosurgery"
DOI: 10.1016/j.wneu.2020.06.069
Abstract: BACKGROUND Andexanet alfa, a novel anticoagulation reversal agent for Factor Xa inhibitors, was recently approved. Traumatic intracranial hemorrhage presents a prime target for this drug. The ANNEXA-4 study established the efficacy of andexanet alfa in… read more here.
Keywords: reversal; factor inhibitors; andexanet; hemorrhage ... See more keywords
Differential Neutralization of Unfractionated Heparin and Enoxaparin by Andexanet Alfa
Sign Up to like & getrecommendations! Published in 2022 at "Clinical and Applied Thrombosis/Hemostasis"
DOI: 10.1177/10760296221099934
Abstract: Introduction Andexanet alfa (andexanet) is an approved antidote used to reverse the bleeding effects of Direct Oral Anticoagulant (Direct-Xa agents) agents because it reverses anti-Xa activity. Unfractionated heparin (UFH) and low molecular weight heparins (LMWHs)… read more here.
Keywords: neutralization; act; andexanet; ufh lmwh ... See more keywords
Heparin Insensitivity and Thrombotic Risk Associated With Sequential Uses of Prothrombin Complex Concentrate and Andexanet Alfa for Apixaban Reversal During Acute Type A Aortic Dissection Repair: A Case Report
Sign Up to like & getrecommendations! Published in 2022 at "A&a Practice"
DOI: 10.1213/xaa.0000000000001636
Abstract: The management of patients on direct oral anticoagulants (DOACs) who require emergent cardiac surgery is slowly evolving. The introduction of andexanet alfa, a novel antidote for apixaban and rivaroxaban, added a specific reversal agent to… read more here.
Keywords: complex concentrate; apixaban; andexanet; reversal ... See more keywords
Andexanet alfa effectively reverses edoxaban anticoagulation effects and associated bleeding in a rabbit acute hemorrhage model
Sign Up to like & getrecommendations! Published in 2018 at "PLoS ONE"
DOI: 10.1371/journal.pone.0195122
Abstract: Introduction Increasing use of factor Xa (FXa) inhibitors necessitates effective reversal agents to manage bleeding. Andexanet alfa, a novel modified recombinant human FXa, rapidly reverses the anticoagulation effects of direct and indirect FXa inhibitors. Objective… read more here.
Keywords: anticoagulation; fxa; andexanet; anti fxa ... See more keywords
Prothrombin complex concentrates and andexanet for management of direct factor Xa inhibitor related bleeding: a meta-analysis.
Sign Up to like & getrecommendations! Published in 2021 at "European review for medical and pharmacological sciences"
DOI: 10.26355/eurrev_202103_25428
Abstract: There are potential concerns related to bleeding caused by oral anticoagulants, especially in the elderly. Andexanet alfa has been authorized for use to reverse the effects of oral anticoagulants. Off-label use of four factor prothrombin… read more here.
Keywords: use; andexanet; pcc; factor ... See more keywords